Potential new treatment may protect celiac patients from gluten-induced injury

The gluten-specific enzyme ALV003 reduces a patient's exposure to gluten and its potential harm, according to a new phase 2 study appearing in Gastroenterology1, the official journal of the American Gastroenterological Association. This study is the first to find that a non-dietary intervention can potentially benefit celiac disease patients.

Study participants were put on an everyday -free diet, challenged with up to 2 grams of gluten daily (equivalent to approximately one half of a standard slice of bread in the U.S.). Researchers found that daily oral administration of ALV003, at the time of gluten ingestion, decreased gluten-induced injury to the small intestine. The treatment appeared to be well tolerated. Gastrointestinal symptoms, such as nausea and abdominal pain, were greater in the placebo group compared with those receiving active treatment.

"Total avoidance of gluten is, at best, challenging," said lead study author, Marja-Leena Lahdeaho, University of Tampere, Tampere University Hospital, Finland. "The potential of ALV003 for is significant given that ongoing exposure to low levels of gluten can cause patients to experience persistent symptoms and , despite following a strict gluten-free diet."

Gluten is widely used in the food and other industries. Cross contamination during food processing is difficult to avoid and the labeling of food products can be inaccurate, misleading or incorrect. The gluten-free diet is socially troublesome, expensive and compliance is problematic. Additionally, traces of gluten can be found in common items such as envelope glue and makeup. These challenges lead to consumption of small amounts of gluten in even the most cautious patients. Thus, there is a need for the development of a pharmacologic therapy that will work with or replace a gluten-free diet.

As the first evidence of a therapeutic intervention for celiac disease meeting primary endpoints, this randomized, double-blind, placebo-controlled clinical trial is a welcomed addition to celiac research. Future studies are warranted before ALV003 can come to market; a 500-person multi-center trial is currently ongoing.

More information: 1. Lähdeaho, Marja-Leena et al. Glutenase ALV003 Attenuates Gluten-Induced Mucosal Injury in Patients With Celiac Disease. Gastroenterology 2014; 146(7): 1649 - 1658; www.gastrojournal.org/article/… 0016-5085(14)00242-X

add to favorites email to friend print save as pdf

Related Stories

Top 5 myths about gluten

Jun 06, 2014

In the past few years there has been a surge in gluten-free diets and products that claim giving up the protein can lead to healthier lifestyles. A New York Times article recently cited Mintel, a market research ...

Some 'low-gluten' beer contains high levels of gluten

Dec 21, 2011

Beer tested in a new study, including some brands labeled "low-gluten," contains levels of hordein, the form of gluten present in barley, that could cause symptoms in patients with celiac disease (CD), the ...

Non-celiac gluten sensitivity's existence questioned

Aug 23, 2013

(HealthDay)—There is no evidence that gluten is a trigger in patients with non-celiac gluten sensitivity (NCGS) placed on a low fermentable, oligo-, di-, monosaccharides, and polyols (FODMAP) diet, according ...

Recommended for you

Liberia holds Senate vote amid Ebola fears

2 hours ago

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate vote that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

22 hours ago

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

Bacteria in caramel apples kills at least four in US

22 hours ago

A listeria outbreak believed to originate from commercially packaged caramel apples has killed at least four people in the United States and sickened 28 people since November, officials said Friday.

Steroid-based treatment may answer needs of pediatric EoE patients

23 hours ago

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

Discovery of genes that predispose a severe form of COPD

Dec 19, 2014

A study by Ramcés Falfán-Valencia, researcher at the National Institute of Respiratory Diseases (INER), found that the mestizo Mexican population has a number of variations in certain genes that predispose ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.